recruited 179 patients with advanced EGFR-mutated NSCLC, and the results showed that bevacizumab combined with EGFR-TKI regimen could significantly improve PFS (14 vs 9.7months, P=0.034) in patients with TP53 co-mutation compared with EGFR-TKI single drug (38). Here, TP53 is linked to non-small cell lung carcinoma.